On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Govt Disclosing Suspected Vaccine Reactions Less Frequently after Expert Advice: Minister
March 22, 2021
- MHLW Panel Hails Use of Clinical Research Data for Regulatory Submissions, but Wants Requirements to Ensure Safety
March 22, 2021
- MHLW to Set Up Medical Supply Office in April after COVID-19, Antibiotic Shortage
March 19, 2021
- Japan to Boost Screening of Coronavirus Variants: Minister
March 19, 2021
- Japan IP High Court Snubs Ex-Grad Student's Appeal over Opdivo Patent Claim
March 19, 2021
- Monitoring Panel to Require MHLW's Periodic Reports on Products Designated for Sakigake Review, Conditional Early Approval
March 18, 2021
- MHLW to Continue Looking into Cause of Generic Scandals: Minister
March 17, 2021
- All Municipalities to Get 2nd Doses for HCPs by Week of May 10: Minister
March 15, 2021
- No Significant Concerns Observed with Pfizer COVID-19 Vaccine: Japan Safety Panels
March 15, 2021
- Site Pain Common with COVID-19 Vaccine, but It Improves in 3 Days: Safety Follow-Up
March 15, 2021
- MHLW Don’t Rule Out 7 Doses per Vial, but Won’t Recommend It for Pfizer Vaccine: Minister
March 15, 2021
- MHLW Panel Determines Medical Need for 4 Drugs Including Acetaminophen
March 15, 2021
- Olumiant, 7 More APIs Earn Orphan Designation: MHLW
March 12, 2021
- 2nd-Dose Shot Starts for COVID-19 Vaccination in Japan
March 12, 2021
- AMED to Fund 22 More Projects to Develop COVID-19 Treatments
March 11, 2021
- Govt Won’t Widely Recommend Use of 7-Dose Syringes for Pfizer Vaccine: Top Spokesman
March 10, 2021
- Medical Institutions Would Be Allowed to Provide 7 Doses per Vial of Pfizer’s COVID-19 Vaccine: Health Minister
March 10, 2021
- PMDA to Launch Working Group in April to Step Up Use of RWD
March 10, 2021
- Japan to Consider Ways to Speed Up Ivermectin Research for COVID-19
March 9, 2021
- Imfinzi, 2 Other Drugs under PMDA Safety Review
March 8, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…